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Introduction: Giant cell arteritis (GCA) is an autoimmune disease commonest in Northern Europe and Scandinavia.
Previous studies report various associations with HLA-DRB1*04 and HLA-DRB1*01; HLA-DRB1 alleles show a gradient in
population prevalence within Europe. Our aims were (1) to determine which amino acid residues within HLA-DRB1 best
explained HLA-DRB1 allele susceptibility and protective effects in GCA, seen in UK data combined in meta-analysis with
previously published data, and (2) to determine whether the incidence of GCA in different countries is associated with
the population prevalence of the HLA-DRB1 alleles that we identified in our meta-analysis.
Methods: GCA patients from the UK GCA Consortium were genotyped by using single-strand oligonucleotide
polymerization, allele-specific polymerase chain reaction, and direct sequencing. Meta-analysis was used to compare
and combine our results with published data, and public databases were used to identify amino acid residues that may
explain observed susceptibility/protective effects. Finally, we determined the relationship of HLA-DRB1*04 population
carrier frequency and latitude to GCA incidence reported in different countries.
Results: In our UK data (225 cases and 1378 controls), HLA-DRB1*04 carriage was associated with GCA susceptibility
(odds ratio (OR) = 2.69, P = 1.5×10−11), but HLA-DRB1*01 was protective (adjusted OR = 0.55, P = 0.0046). In meta-analysis
combined with 14 published studies (an additional 691 cases and 4038 controls), protective effects were seen from
HLA-DR2, which comprises HLA-DRB1*15 and HLA-DRB1*16 (OR = 0.65, P = 8.2×10−6) and possibly from HLA-DRB1*01
(OR = 0.73, P = 0.037). GCA incidence (n = 17 countries) was associated with population HLA-DRB1*04 allele frequency
(P = 0.008; adjusted R2 = 0.51 on univariable analysis, adjusted R2 = 0.62 after also including latitude); latitude also made
an independent contribution.
Conclusions: We confirm that HLA-DRB1*04 is a GCA susceptibility allele. The susceptibility data are best explained by
amino acid risk residues V, H, and H at positions 11, 13, and 33, contrary to previous suggestions of amino acids in the
second hypervariable region. Worldwide, GCA incidence was independently associated both with population frequency
of HLA-DRB1*04 and with latitude itself. We conclude that variation in population HLA-DRB1*04 frequency may partly
explain variations in GCA incidence and that HLA-DRB1*04 may warrant investigation as a potential prognostic or
predictive biomarker.* Correspondence: a.w.morgan@leeds.ac.uk
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Genetic association studies are a well-established method
for investigating genetic contributions to disease. In
rheumatoid arthritis (RA) [1] and small-vessel vasculitis
[2], genetically distinct subsets have been identified that
have different associations with the major histocompatibil-
ity complex (MHC) region that encodes the HLA-DRB1
alleles. Comparison of HLA-DRB1 associations with RA in
different ethnic groups helped to support the original
“shared epitope” hypothesis of RA susceptibility [3] based
on an amino acid risk motif at positions 67–74 in the third
hypervariable region (HVR3) of the class II MHC mol-
ecule, encoded by HLA-DRB1. The group of RA “shared
epitope” alleles now includes HLA-DRB1*01:01, HLA-
DRB1*04:01, HLA-DRB1*04:04, HLA-DRB1*04:08, and
HLA-DRB1*10:01; other alleles provide weaker protective
effects, additional to the risk effects of the “shared epitope”
[4]. Recently, it has been demonstrated that amino acid
residues 11 and 13 in the first hypervariable region
(HVR1) of class II MHC display the strongest associations
with RA susceptibility [5].
Giant cell arteritis (GCA) incidence is highest in pop-
ulations with Scandinavian ancestry [6–8] and this has
led to suggestions that this might be due to genetic fac-
tors [9, 10]. Susceptibility to GCA has been reported to
be associated with carriage of HLA-DRB1*04, but not
all studies have shown an association and there are
conflicting data as to whether there is an association
with specific HLA-DRB1*04 alleles [11]. Under-
representation of HLA-DRB1*01 in GCA patients from
Rochester, Minnesota, led to a suggestion that the risk of
GCA may be due to a DRYF motif at positions 28–31 in
the second hypervariable region (HVR2) of MHC class
II [12], but a Spanish study failed to replicate this find-
ing [13]. To date, however, formal meta-analysis has not
yet been performed to determine the major susceptibil-
ity and protective HLA-DRB1 alleles. The relative con-
tribution of genetic and environmental factors as an
explanation for geographical differences in GCA inci-
dence also remains disputed [6, 7]. When genetic diver-
sity within Europe is subjected to principal component
analysis, the MHC is one of several genetic regions that
are strongly associated with a component that runs
along a north-south gradient from Norway/Sweden to
Spain [14]. We therefore hypothesised that variations
in the frequency of HLA-DRB1 GCA susceptibility al-
leles may partly explain geographical variations in
GCA incidence.
Here, we report new GCA susceptibility data, combine
these with the published data using meta-analysis, and
propose a new hypothesis regarding a possible amino
acid GCA 11-13-33 risk motif in HVR1 and HVR2 of
class II MHC. This hypothesis fits the observed data
better than previously proposed models.Methods
Patients
The UK GCA Consortium was designed to support gen-
etic association studies. Investigators, all experienced
rheumatologists, recruited cases with a firm clinical diag-
nosis of GCA, based on all available information. Recruit-
ment was retrospective. A positive temporal artery biopsy
was not required as it was not always undertaken in classic
presentations or could not be performed within an opti-
mal time window or both. In some centres, the erythro-
cyte sedimentation rate was unavailable and so fulfilment
of the 1990 American College of Rheumatology (ACR) cri-
teria [15], which should not be used for clinical diagnosis
of GCA [16], was not a requirement for inclusion. Clinical
data on a subset of this cohort have already been pub-
lished [17]. In this analysis, we included all patients who
agreed to give a blood sample for genetic studies up to
2012 and where a sample was available. Written informed
consent was provided by all patients, and the study was
approved by the York Research Ethics Committee (refer-
ence 05/Q1108/28).
DNA extraction and genotyping
DNA was extracted from peripheral blood. HLA-DRB1
genotyping was performed by either single-stranded
oligonucleotide polymerisation [18] or allele-specific
polymerase chain reactions (standard primer sequences
(HLA DRBplus Typing Kit, Amersham Biosciences, now
part of GE Healthcare, Little Chalfont, UK), except for
the forward primer of HLA-DRB1*10 which was rede-
signed as 5'-GCG GTT GCT GGA AAG ACG CG-3').
Direct sequencing was also performed to enable four-
digit genotyping of HLA-DRB1*04 subtypes [18] because
of previous reports of a HLA-DRB1*04 association of
GCA at the two-digit level. The HaplotypeViewer pro-
gram was developed to facilitate rapid four-digit geno-
typing from sequence electropherograms and is freely
available [19].
Analysis of genotyping data
Control data from the UK Rheumatoid Arthritis Genetics
(UKRAG) Consortium were used for this analysis. Initial
logistic regression analyses were undertaken by assuming
additive genetic models to estimate the effect of each po-
tential susceptibility/protective allele. Adjustments for
genetic effects already proposed in the literature (HLA-
DRB1*04) were also performed.
Meta-analysis of giant cell arteritis susceptibility data
To identify case-control studies of HLA-DRB1 associ-
ation with GCA susceptibility, a literature search was
conducted in PubMed, without language restriction, by
using the terms “HLA” and “(giant cell arteritis) OR
(temporal arteritis)”. Reference lists of studies identified
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provided sufficient detail on cases and controls to per-
form a meta-analysis. Where there were multiple publi-
cations with overlapping datasets, the report with the
most complete dataset was chosen. Meta-analysis of the
published summary carrier frequency data was per-
formed (i.e., assuming a dominant mode of inheritance)
because allele frequency and individual-level patient data
were mostly unavailable from the authors of the studies.
A random-effects model was used; the overall estimate
was calculated by using as weights 1/(vi + τ), where vi is
the variance of the estimated effect from the ith study
and τ is the estimated between-study variance [20].
Worldwide giant cell arteritis incidence in relation to
HLA-DRB1*04 population carrier frequencies
To identify reports of the incidence of GCA in different
countries, a second literature search in PubMed was
conducted with combinations of the medical subject
heading terms “giant cell arteritis”, “temporal arteritis”,
and “epidemiology”. Hand-searching was also performed
in the reference lists of retrieved articles, review articles,
and textbooks. Studies were included if they were avail-
able in full-text and included an estimate of the annual
incidence, time period of the study, method of case def-
inition, population studied, and geographical location of
the study. Where necessary, the incidence figure was
recalculated as number of new cases per 100,000 of the
over-50 population per year. Studies that appeared to re-
port duplicate or overlapping populations were excluded.
Studies completing recruitment before 1980 were ex-
cluded in case of time trends in the incidence of GCA
and because the quality of the reporting was generally
lower for the older studies. Where more than one report
existed for a single country (unless in ethnically distinct
populations), the one with a later average period of re-
cruitment was preferred. Where a single report included
two separate sub-studies (regions or time periods), a
weighted mean of the two sub-studies was used to arrive
at an overall incidence figure.
We then sought data on ethnically matched HLA-
DRB1 population allele frequencies at the two- and four-
digit levels for each geographical region identified in the
second literature search. We considered HLA-DRB1*04
alleles and those identified as being potential susceptibil-
ity/protective alleles in our own UK dataset. Methods
have been reported elsewhere [21]; briefly, we first con-
sulted the Allele Frequency Net Database [22] and then,
if necessary, Ovid Medline and Embase. Carrier frequen-
cies for control populations were converted to estimated
allele frequencies by using the Hardy-Weinberg equa-
tion. Finally, the following predetermined rule was used
to generate an estimate of population HLA-DRB1 allele
frequencies: reports with over 500 (four-digit typing) or1000 (two-digit typing) controls were identified and a
weighted mean calculated. In the absence of large stud-
ies, studies with more than 100 (four-digit typing) or
more than 200 (two-digit typing) were identified and a
weighted mean calculated. Determination of geograph-
ical latitude and linear regression analysis were per-
formed as previously described [21].
Development of amino acid risk motif model
After determination of susceptibility and protective
HLA-DRB1 alleles, amino acid residues in HVR1, HVR2,
and HVR3 were obtained from the IMGT (International
ImMunoGeneTics Information System) database [23],
accessed 31 January 2012). For samples with only two-
digit typing, we estimated amino acid residues on the
basis of geographically relevant population frequencies
of the four-digit subtypes from the Allele Frequency Net
Database [22], assigning a probability to residues when
they varied within the four-digit subtypes (only neces-
sary at positions 28, 32, 37, 67, 70, 71, and 74). For each
of these, the expected misclassification rate when
assigned by using population frequencies is less than 1
%, apart from positions 67 (2 %) and 71 (3 %). For each
polymorphic position, samples were assigned a dosage
(i.e., the expected number of copies) for each residue.
Logistic regression was then used to test for association
at each position separately, and degrees of freedom were
equal to one less than the number of distinct residues.
For the most significant positions, forward stepwise re-
gression was used to identify the residues associated
with disease risk at that position.
We used population HLA-DRB1 frequencies for infer-
ring amino acid residues in both cases and controls.
Under the null hypothesis of no association, the frequen-
cies would be the same, and any bias introduced by
using population frequencies for cases would be toward
the null. Using HLA-DRB1 four-digit frequencies that
have been observed in patients with GCA to infer the
amino acid residues in the GCA cases could lead to a
biased analysis with inflated false-positive rate.
Results that reach a nominal significance level of 0.05
are highlighted. For the exploratory hypotheses, these
should be interpreted in the light of multiple testing.
Analyses were performed in SPSS 15 (IBM Corporation,
Armonk, NY, USA) and Stata SE (StataCorp LP, College
Station, TX, USA).
Results
Patients
Two hundred twenty-five patients with GCA from 7 UK
centres consented to analysis of genetic material for this
study (125 from Leeds hospitals, including 38 from
Otley; 33 from Harrogate; 23 from Southend; 17 from
York; 16 from Dewsbury; 10 from Pontefract; and one
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teristics, including fulfilment of 1990 ACR criteria, are
shown in Table 1. Of the 183 temporal artery biopsies
performed, 140 (77 %) were positive. Patients were all
European Caucasian.
Analysis of genotyping data
Allele frequencies in cases and 1378 UKRAG controls
are shown in Table 2 with per-allele odds ratios with and
without adjustment for HLA-DRB1*04, the previously
proposed susceptibility allele. Initial analysis was per-
formed at the two-digit level. Four-digit analysis was also
performed for the common *04 subtypes, but statistical
analysis was not performed on the rarer *04 subtypes.
In 225 patients with GCA and 1378 controls in the
novel UK cohort, a susceptibility effect of HLA-DRB1*04
carriage was confirmed (odds ratio (OR) 2.69, 95 % con-
fidence interval (CI) 2.02 to 3.58, P = 1.5×10−11)
(Table 3). Possible protective effects from HLA-DRB1*01
and HLA-DRB1*15 were noted, but only HLA-DRB1*01
retained significance after adjusting for HLA-DRB1*04
(Table 2). The data were consistent with a dominant ef-
fect of HLA-DRB1*04 (OR for one copy 2.78, 95 % CI
2.07 to 3.72, OR for two copies 1.94, 95 % CI 0.95 to
3.96, compared with no copies).
The effect sizes for HLA-DRB1*04 carriage were simi-
lar when restricting analyses to biopsy-positive GCA
cases (OR = 2.83, 1.99 to 4.03, P = 7.7×10−9); the num-
ber of biopsy-negative GCA cases was too small for a
separate analysis.
Meta-analysis of giant cell arteritis susceptibility data
Meta-analysis of previously published data from 14 stud-
ies (691 cases, 4038 controls; Table 3) gave ORs of 2.45
(P = 9.2×10−24), 0.78 (P = 0.11), and 0.71 (P = 0.0019)Table 1 Patient characteristics
Patient characteristic V
Female 1
Median age at onset of GCA (range), years 7
Biopsy-positive 1
Median erythrocyte sedimentation rate at onset of GCA (range), mm/h 7
Median plasma viscosity at onset of GCA (range), mPa s 1
Median C-reactive protein at onset of GCA (range), mg/l 6
Either ACR 1990 criteria for GCA fulfilled or biopsy-positive 2
Headache 1
Abnormal temporal artery as defined by ACR 1990 criteria 1
Jaw claudication 1
Visual or neurological features 1
Owing to the retrospective recruitment of cases, contemporaneously recorded data
recorded in the medical notes. For this reason, in 24 cases, fulfilment of American C
were biopsy-proven. In some recruiting centres, plasma viscosity or C-reactive protefor HLA-DRB1*04, *01, and *02, respectively (*02 is now
reclassified as *15 and *16). There was more heterogen-
eity noted for some alleles than for others; the HLA-
DRB1*04 meta-analysis had an I2 statistic of 0 % whereas
the meta-analysis for HLA-DRB1*01 had an I2 statistic
of 39.4 %. When our UK data was included, the meta-
analysis still demonstrated protective effects for HLA-
DRB1*01 and HLA-DRB1*02 (P = 0.037 and P = 8.2×10
−6, respectively) (Table 3). In the six published articles with
information on ethnicity, cases and controls were always
stated to be either “white” or “Caucasian”. Therefore, sub-
group meta-analysis by ethnic group was not possible.
Worldwide giant cell arteritis incidence in relation to
HLA-DRB1*04 population carrier frequencies
Reliable population HLA-DRB1 data were not always
available, notably for small, native tribes of Alaska and
Saskatoon, where extrapolation from small and physic-
ally or genetically (or both) isolated communities was
felt to be unwarranted. Table 4 summarises the GCA in-
cidence articles included, together with the estimated
population allele frequencies and the number of individ-
uals on which these estimates are based. Substantial
clinical heterogeneity was identified in the GCA inci-
dence studies, including variations in the methods used
to identify GCA cases and confirm GCA diagnosis.
At the two-digit level (Table 4 and Fig. 1a and b), 17
studies were included in the analysis of worldwide GCA
incidence in relation to population HLA-DRB1 allele
frequencies. In view of our meta-analysis findings, we ex-
tracted data for HLA-DRB1*04, HLA-DRB1*01, and HLA-
DRB1*15 population frequencies (Table 4). The majority
of these were from Europe and the Mediterranean area.
Within this small dataset, HLA-DRB1*15 was more com-
mon in the general population at more northerly latitudesalue (% of those with data available) Number with data available
61 (72 %) 225
2 (50–94) 207
40 (77 %) 183 (number of cases biopsied)
0 (5–150) 100
.94 (1.53–2.65) 120
2.5 (<5–344) 154
07 (92 %) 225
84 (90 %) 204
40 (67 %) 204
19 (57 %) 210
16 (56 %) 207
on features of giant cell arteritis (GCA) at presentation were not always
ollege of Rheumatology (ACR) criteria could not be documented. Six of these
in was measured instead of erythrocyte sedimentation rate
Table 2 Allele frequencies and per-allele odds ratios in giant cell arteritis cases and controls
HLA-DRB1 allele Allele frequency
in controls, N (%)
Allele frequency
in cases, N (%)
Allele frequency in
biopsy-positive cases, N (%)
Unadjusted OR (95 % CI) P value OR adjusted
for *04 (95 % CI)
P value
*01 341 (12.4) 27 (6.0) 12 (4.3) 0.46 (0.31, 0.69) 1.6×10−4 0.55 (0.37, 0.83) 0.0046
*03 438 (15.9) 75 (16.7) 41 (14.5) 1.06 (0.81, 1.39) 0.68 1.31 (0.99, 1.74) 0.061
*04 503 (18.3) 138 (30.7) 89 (31.6) 2.03 (1.61, 2.56) 1.7×10−9 - -
*04:01 304 (11.0) 83 (18.4) 54 (19.1) 1.87 (1.42, 2.46) 8.2×10−6 - -
*04:02 10 (0.4) 2 (0.4) 1 (0.4) 1.29 (0.64, 2.59)* 0.48* - -
*04:03 38 (1.4) 8 (1.8) 7 (2.5)
*04:04/04:08 151 (5.5) 45 (10.0) 27 (9.6) 1.86 (1.32, 2.63) 3.7×10−4 - -
*07 393 (14.3) 57 (12.7) 34 (12.1) 0.88 (0.65, 1.17) 0.37 1.03 (0.76, 1.39) 0.85
*08 78 (2.8) 8 (1.8) 4 (1.4) 0.62 (0.30, 1.29) 0.20 0.75 (0.36, 1.57) 0.45
*09 30 (1.1) 5 (1.1) 5 (1.8) 1.02 (0.39, 2.66) 0.97 1.19 (0.45, 3.12) 0.73
*10 21 (0.8) 0 (0.0) 0 (0.0) - - -
*11 179 (6.5) 32 (7.1) 20 (7.1) 1.09 (0.75, 1.59) 0.64 1.25 (0.86, 1.83) 0.25
*12 49 (1.8) 10 (2.2) 6 (2.1) 1.24 (0.64, 2.42) 0.53 1.60 (0.81, 3.14) 0.18
*13 222 (8.1) 41 (9.1) 32 (11.3) 1.14 (0.81, 1.62) 0.45 1.35 (0.95, 1.93) 0.098
*14 60 (2.2) 10 (2.2) 5 (1.7) 1.02 (0.52, 2.00) 0.95 1.29 (0.65, 2.56) 0.46
*15 421 (15.3) 45 (10.0) 32 (11.3) 0.63 (0.46, 0.87) 0.0047 0.75 (0.54, 1.04) 0.085
*16 21 (0.8) 2 (0.4) 2 (0.7) 0.58 (0.13, 2.49) 0.46 0.67 (0.16, 2.92) 0.60
N number of copies of allele seen in 1378 controls or 225 cases, OR odds ratio, CI confidence interval
*denotes where HLA-DRB1*04:02 and *04:03 categories were combined because of low numbers
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with latitude was seen for population HLA-DRB1*04 or
HLA-DRB1*01 (r = 0.47, P = 0.057; r = 0.39, P = 0.133).
Predictors of GCA incidence in univariable analyses
were HLA-DRB1*04 population allele frequency (P =
0.001, adjusted R2 = 0.51) and latitude (P = 0.004, ad-
justed R2 = 0.40), whereas HLA-DRB1*15 was non-
significant. In multivariable analysis, both were significant
predictors and each made independent contributions to
the explanatory power of the model (HLA-DRB1*04, P =
0.008; latitude, P = 0.036; adjusted R2 of the model =
0.62). HLA-DRB1*15 made no additional contribution to
the explanatory power of the model.Development of model with 11-13-33 amino acid risk motif
Tests for association showed that the most significant pos-
ition was at 13 (P = 1.2×10−9), followed by 11, 33, 37, and
9 (Fig. 1c). At position 13, the most significant residue was
H (OR = 2.11, 95 % CI 1.61 to 2.77, P = 5.5×10−8, equiva-
lent to H at 33 and also to the 04 allele). However, step-
wise regression found additional contributions from
residues S (OR = 1.38, 95 % CI 1.07 to 1.77, P = 0.014)
and F (OR = 0.66, 95 % CI 0.44 to 0.99, P = 0.038)
(Table 5). Similarly, multiple residues were found at posi-
tions 11 and 37. There is very strong linkage disequilib-
rium in this region, and so many of these residues at
different positions almost always occur together, asillustrated in Additional file 1. For example, we did not
have the power to distinguish between the risk effects of
V, H, and H at positions 11, 13, and 33, respectively, since
the *10 allele, which differs at residue 13, is very rare. The
previously proposed DYF motif (positions 28, 30, and 31)
in HVR2 (OR = 1.54, 95 % CI 1.21 to 1.96, P = 0.00038)
did not explain the observed data as well as simple HLA-
DRB1*04 carriage. Similarly, variation in amino acid resi-
dues within HVR3 is unlikely to explain the observed
GCA susceptibility data (Fig. 1c), especially since the other
alleles comprising the “RA shared epitope” were not over-
represented in GCA.Discussion
In this study, which includes both new UK data and the
first formal meta-analysis of published data on HLA-
DRB1 associations of GCA, we not only confirm a
strong association of GCA with HLA-DRB1*04 allele
carriage, including within our own UK data, but also
identify possible protective effects of HLA-DRB1*01 and
HLA-DRB1*15, supported by the meta-analysis of previ-
ous studies. We were able to impute amino acid residues
quite reliably from published allele frequencies, enabling
us to analyse amino acid residues even though four-digit
typing was not available for every HLA-DRB1 allele.
Based on this, it was the amino acid residues 11, 13, and
33 in the first and second hypervariable regions that best
Table 3 Meta-analysis of HLA-DRB1 giant cell arteritis associations in the literature
HLA-DRB1 allele(s) UK GCA Cohort Published data only Combination of data in this report with published data
OR (95 % CI) for carriage of allele P value Number of studies OR (95 % CI) for
carriage of allele
Meta-analysis
P value
Heterogeneity
I2 statistic (%)
Number of
studies
OR (95 % CI) for
carriage of allele
Meta-analysis
P value
Heterogeneity
I2 statistic (%)
*01 0.46 (0.30, 0.70) 0.00033 14 0.78 (0.57, 1.06) 0.11 39.4 15 0.73 (0.54, 0.98) 0.037 48.1
DR2 (*15 and *16) 0.53 (0.37, 0.76) 0.00050 13 0.71 (0.57, 0.88) 0.0019 0 14 0.65 (0.54, 0.79) 8.2×10−6 0
*03 1.12 (0.83, 1.52) 0.47 14 1.02 (0.81, 1.28) 0.87 10.0 15 1.05 (0.88, 1.27) 0.58 4.2
*04 2.69 (2.02, 3.58) 1.5×10−11 15 2.45 (2.06, 2.92) 9.2×10−24 0 16 2.51 (2.16, 2.92) 1.1×10−33 0
*05 (*11 and *12) 1.21 (0.83, 1.75) 0.32 9 0.85 (0.65, 1.12) 0.24 0 10 0.96 (0.77, 1.20) 0.72 0
*06 (*13 and *14) 1.11 (0.78, 1.57) 0.56 10 0.69 (0.48, 0.99) 0.042 27.1 11 0.76 (0.55, 1.06) 0.11 40.6
*07 0.92 (0.66, 1.28) 0.63 14 1.14 (0.81, 1.60) 0.45 65.0 15 1.12 (0.83, 1.50) 0.47 63.4
*11 1.18 (0.78, 1.79) 0.43 6 0.90 (0.65, 1.26) 0.55 6.9 7 1.00 (0.77, 1.30) 0.98 5.1
*13 1.15 (0.79, 1.68) 0.47 5 0.68 (0.47, 1.00) 0.050 0 6 0.89 (0.68, 1.16) 0.39 0
GCA giant cell arteritis, OR odds ratio, CI confidence interval
Insufficient data were present for HLA-DRB1*08, *09, *10, *12, *14, *15 and *16 to perform meta-analysis. Published studies included in this meta-analysis for each allele were HLA-DRB1*01/*03/*07 [13, 36–48],
HLA-DRB1*02 [13, 36–46, 48], HLA-DRB1*05 [13, 36–39, 41–43, 46], HLA-DRB1*06 [13, 36–39, 41–44, 46], HLA-DRB1*11 [13, 40, 44, 45, 47, 48], and HLA-DRB1*13 [13, 40, 45, 47, 48]
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Table 4 Incidence of giant cell arteritis and population HLA-DRB1 allele frequencies in different countries
GCA incidence study HLA-DRB1 allele frequency and references (if multiple references given, the allele frequency is the weighted mean)
City/region,
country, reference
Dates, study
design
GCA criteria GCA incidence,
per 100,000 per
year in over-50s
Latitude
(degrees N)
*04 *01 *15 *04:01 *04:04
W Nyland,
Finland [49]
1987-88,
prospective
Biopsy, clinical 26.2 61.5 0.147 (n = 1157 [50]) 0.183 (n = 1157 [50]) 0.144 (n = 1157 [50]) 0.080
(n = 1157 [50])
0.037 (n = 1157 [50])
Goteborg,
Sweden [51]
1976-95,
retrospective
Biopsy, clinical 22.2 57.7 0.195 (n = 1347 [22],
1366 [52], 1209 [53],
1191 [54])
0.105 (n = 1347 [22],
1366 [52], 1209 [53],
1191 [54])
0.159 (n = 1347 [22],
1366 [52], 1209 [53],
1191 [54])
0.137 (n = 934
[55], 1763 [56],
1191 [54])
0.057 (n = 934 [55],
1763 [56], 1191 [54])
Reggio Emilia,
Italy [57]
1980-88,
retrospective
Biopsy 6.9 44.7 0.072 (n = 57,345 [58],
4080 [22], 2054 [22],
1992 [59])
0.089 (n = 57,345 [58],
4080 [22], 2054 [22],
1992 [59])
0.068 (n = 57,345 [58],
2054 [22], 1992 [59])
0.017
(n = 57,345 [58])
0.012 (n = 57345 [58])
Lugo, NW
Spain [60]
1981-98,
retrospective
Biopsy 10.2 43.0 0.129 (n = 1940 [61],
1088 [62])
0.103 (n = 1940 [61],
1088 [62])
0.104 (n = 1940
[61], 1088 [62])
0.053
(n = 145 [22])
0.0207 (n = 145 [22])
Denmark [63] 1982-94,
prospective
Biopsy 20.4 56.5 0.180 (n = 562 [64]) 0.101 (n = 562 [64]) 0.157 (n = 562 [64]) 0.176
(n = 55 [22])
0.001 (n = 55 [22])
Iceland [65] 1984-90,
retrospective
ACR 1990 criteria 27.0 64.7 0.170 (n = 172 [66]) 0.040 (n = 172 [66]) 0.020 (n = 172 [66]) No data No data
Alesund and
Bodo, Norway [67]
1992-6,
retrospective,
hospital
Biopsy/ACR
1990 criteria
32.4 64.9 0.225 (n = 576 [22],
630 [68], 368 [69],
898 [55])
0.117 (n = 576 [22],
630 [68], 898 [55])
0.153 (n = 576 [22],
630 [68], 368 [69],
898 [55])
0.117
(n = 898 [55])
0.067 (n = 898 [55])
Schleswig
Holstein, North
Germany [70]
1998-2002,
prospective,
population
Chapel Hill
consensus criteria
3.2 54.2 0.140 (n = 11,407 [22],
8862 [22], 4251 [71])
0.111 (n = 11,407 [22],
8862 [22], 4251 [71])
0.141 (n = 11,407
[22], 8862 [22],
4251 [71])
0.081
(n = 8862 [22])
0.024 (n = 8862 [22])
Vilnius, Lithuania [72] 1990-9,
prospective,
hospital
ACR 1990 criteria 0.7 54.7 0.078 (n = 134 [73]) 0.111 (n = 134 [73]) No data No data No data
Jerusalem [74] 1980-2004,
retrospective
Biopsy + ACR
1990 criteria
11.3 31.8 0.170 (n = 23000 [22]) 0.083 (n = 23,000 [22]) 0.070 (n = 23,000 [22]) 0.019
(n = 132 [75])
0.015 (n = 132 [75])
Sephardic Jews,
Israel [76]
1980-91,
retrospective
Biopsy 10.2 31.8 0.112 (n = 293 [77]) 0.038 (n = 293 [77]) 0.087 (n = 293 [77]) 0.000
(n = 293 [77])
0.009 (n = 293 [77])
UK [28] 1990-2001,
prospective
Clinical 22.0 51.5 0.204 (n = 39,979
[22], 1238 [78])
0.110 (n = 39,979
[22], 1238 [78])
0.143 (n = 39,979
[22], 1238 [78])
0.116
(n = 298 [22])
0.047 (n = 298 [22])
Erdirne, Turkey [79] 2003-9,
retrospective
Clinical 1.1 41.7 0.128 (n = 250 [22],
253 [80], 250 [81])
0.047 (n = 250 [22],
253 [80], 250 [81])
0.082 (n = 250 [22],
253 [80], 250 [81])
0.014 (n = 110
[82], 250 [81])
0.019 (n = 110 [82],
250 [81])
Olmsted County,
MN, USA [83]
2000-2004,
prospective,
population
ACR 1990 18.9 44.0 0.156 (n = 339 [22]) 0.097 (n = 339 [22]) 0.124 (n = 339 [22]) 0.091
(n = 339 [22])
0.040 (n = 339 [22])
Biopsy/clinical 2.2 35.2 0.031 (n = 61,655 [22])
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Table 4 Incidence of giant cell arteritis and population HLA-DRB1 allele frequencies in different countries (Continued)
White, Memphis,
TN, USA [84]
1971-1980,
retrospective
0.156
(n = 61,655 [22])
0.110
(n = 61,655 [22])
0.133
(n = 61,655 [22])
0.091
(n = 61,655 [22])
Black, Memphis,
TN, USA [84]
1971-1980,
retrospective
Biopsy/clinical 0.4 35.2 0.060 (n = 34 [85]) No data 0.210 (n = 34 [85]) No data No data
Europeans,
Saskatoon, Canada [86]
1998-2003,
prospective
Biopsy 9.3 52.1 0.178 (n = 415 [87]) 0.092 (n = 415 [87]) 0.147 (n = 415 [87]) 0.097
(n = 216 [88])
0.051 (n = 216 [88])
ACR American College of Rheumatology
Giant cell arteritis (GCA) incidence in Finland was taken as weighted mean of the two sub-studies reported in the article cited. Allele frequencies are the weighted mean of the allele frequencies reported in the studies
cited (see Methods for details of how these were selected). For brevity, where the data were taken from the allelefrequencies.net website, the main citation for the website is given [22]; searching allelefrequencies.net
on the country, sample size, and human leukocyte antigen (HLA) allele in question will give the allele frequencies used in this table
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Fig. 1 Giant cell arteritis (GCA) incidence in relation to population HLA-DRB1 allele frequencies (a) and to latitude (b). Significance levels from a
global test of difference in distribution of amino acid frequencies between cases and controls at specific positions (c)
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tective effects, rather than the previously proposed DRYF
amino acid motif in the second hypervariable region [12].
We also observed that some non-HLA-DRB1*04 amino
acid residues had additional effects (individual amino acid
residues that were retained by a multivariable regression
model for each separate amino acid position are shown in
the last two columns in Table 5), suggesting additional
genetic complexities that we did not have the power to in-
vestigate in depth. We then systematically extracted data
on population prevalence of the identified susceptibility
and protective HLA-DRB1 alleles and compared this
with reports of GCA incidence in different countries.
We found a significant and independent relationship of
GCA incidence both with HLA-DRB1*04 and with lati-
tude. Conversely, HLA-DRB1*15 was, if anything, pro-
tective and did not contribute to incidence of GCA in
the geo-epidemiological study.
Strengths of this work include the presentation of the
first UK HLA data in GCA, its presentation in the con-
text of the international literature, the first meta-analysis
of HLA-DRB1*04 GCA susceptibility studies, and the
novel approach combining a traditional genetic associ-
ation study with a geo-epidemiology approach. Using lo-
gistic regression for the UK, we could control for
already-known HLA-DRB1 susceptibility effects in the
per-allele analysis, which also has not been performed inother datasets, which mostly reported only carrier fre-
quencies not allele frequencies. Based on this, we were
able to suggest HLA-DRB1 amino acid residues that best
fit the observed susceptibility/protective allele effects.
This is the first synthesis of the literature on reported
GCA incidence in relation to population HLA-DRB1 al-
lele frequency and geographical latitude.
Our analysis is based on certain assumptions. Firstly,
because many clinicians in the UK do not always request
temporal artery biopsy except in cases of diagnostic
doubt [24], we had prespecified in the analysis that GCA
would be defined clinically rather than limiting inclusion
to biopsy-positive cases only. The clinically diagnosed
patients, however, had to be firmly diagnosed by an ex-
perienced consultant, and there had to be unequivocal
clinical features and no alternative explanation for the
symptoms after follow-up. Temporal artery biopsy is not
100 % sensitive for GCA; possible reasons for false-
negative biopsies in our cohort included delays in obtain-
ing biopsies resulting in resolution of inflammation,
suboptimal biopsy length, and biopsy reporting based on
the classic pathologic criteria, which may be overly strin-
gent [25]; sometimes the temporal artery is spared in pa-
tients with GCA, particularly in those with predominant
disease of the aorta and its proximal branches [26]. We
conducted a sub-analysis of the biopsy-positive subset and
found no difference in the observed effect size for HLA-
Table 5 Results of tests for association of amino acid at the most significant positions: 9, 11, 13, 33, and 37
Position in
HLA-DRB1
Amino
acid residue
Frequency Univariable Stepwise model (entry P = 0.05) applied separately at each position
Cases Controls OR P value OR P value
9 E 0.698 0.565 1.78 7.3×10−8
K 0.011 0.011 1.03 0.96
W 0.291 0.424 0.56 5.8×10−8 0.56 5.85×10−8
11 D 0.011 0.011 1.03 0.96
G 0.127 0.142 0.88 0.38
L 0.060 0.123 0.46 3.6×10−5 0.64 0.040
P 0.104 0.159 0.63 0.0024
S 0.391 0.371 1.09 0.41 1.37 0.015
V 0.307 0.194 1.86 1.4×10−7 2.06 2.8×10−7
13 F 0.071 0.141 0.48 1.7×10−5 0.66 0.038
G 0.040 0.045 0.87 0.60
H 0.307 0.187 1.96 1.5×10−8 2.11 5.5×10−8
R 0.104 0.159 0.63 0.0024
S 0.351 0.325 1.12 0.28 1.38 0.014
Y 0.127 0.142 0.88 0.38
33 H 0.307 0.187 1.96 1.5×10−8 1.96 1.527×10−8
N 0.693 0.813 0.51 1.5×10−8
37 F 0.147 0.161 0.89 0.39
L 0.022 0.017 1.27 0.49
N 0.256 0.219 1.09 0.46
S 0.164 0.282 0.51 8.0×10−8 0.59 0.00012
Y 0.402 0.276 1.63 3.2×10−6 1.37 0.0055
Forward stepwise regression was used to determine whether there are independent effects of more than one amino acid residue at the same position. Only
amino acids that were retained by the stepwise regression model are shown in the last two columns. Odds ratio (OR) of less than 1.0 indicates a protective effect,
whereas OR of more than 1.0 indicates a susceptibility effect. Note the high level of linkage disequilibrium at this locus; Additional file 1 shows the amino acid
residues within the three hypervariable regions of HLA-DRB1
Mackie et al. Arthritis Research & Therapy  (2015) 17:195 Page 10 of 14DRB1*04 association compared with the whole group;
with such a small number of biopsy-negative cases, no
meaningful statement can be made about the effect size in
that group. Our meta-analysis showed that the effect size
in the cohort overall was also comparable to that observed
in previous reports, some of which included only biopsy-
positive cases. If not all the cases truly had GCA, this
would have reduced the power of the study (“diluted out”
the genetic association) but would have been highly un-
likely to introduce artefactual genetic associations because
the differential diagnosis of GCA is so wide. Similar prag-
matic approaches to case definition for genetics studies,
accepting a small, finite rate of misclassification in order
to maximise recruitment, have been successfully used in
other genetic association studies [27]. We also did not
have the power to study whether there are differences in
the effect size between regions of the UK, but regional
variations in the incidence of diagnosed GCA have been
described [28]; it remains unclear how far this is influ-
enced by regional variations in population HLA-DRB1
frequency [29].In regard to the HLA-DRB1 typing, it is recognised
that HLA-DRB1 represents only a small part of the
whole MHC and also that not having complete
sequence-based four-digit typing may have resulted in
some important information being missed. This study
focused on HLA-DRB1 and we did not set out to ana-
lyse variation elsewhere in the MHC [30]. However, our
finding that non-HLA-DRB1*04 residues also contrib-
uted significantly to GCA susceptibility/protection
(Table 5) suggests that other alleles may also be in-
volved. The MHC is a complex locus with extensive
linkage disequilibrium, and an MHC-wide analysis re-
quires larger datasets and specialised analysis methods.
A concurrent international, collaborative large-scale
genetic analysis of GCA (including samples from this
study), using a different genotyping platform (Immuno-
chip) with more extensive coverage of the HLA region
[31], shows evidence of wider involvement of the MHC
region while confirming the strong association with
DRB1*04. Lastly, the literature reviews and meta-
analyses are limited by the small number of studies in
Mackie et al. Arthritis Research & Therapy  (2015) 17:195 Page 11 of 14the literature, many of which were published some years
ago, with corresponding variations in case ascertain-
ment and in genotyping assays. Larger datasets using
modern genotyping and statistical analysis methods will
reveal further GCA susceptibility alleles within the
whole HLA locus and allow their pattern of linkage dis-
equilibrium to be analysed.
The P values reported here should be considered in the
light of multiple testing, but owing to the a priori sugges-
tion of HLA-DRB1*04 association and lack of consensus
as to how to adjust for multiple testing at a multi-allelic
locus where the different alleles are not independent of
each other, we did not consider a Bonferroni correction to
be appropriate here. Nevertheless, model over-fitting is a
possibility, and it is essential that our findings be repli-
cated in an independent dataset.Conclusions
In summary, we report a novel approach to studying gen-
etic influences of disease by combining traditional genetic
association studies with geo-epidemiology methods that
capitalise on publicly available data. Our new UK data and
a synthesis of the published literature suggest that HLA-
DRB1*04 might explain part of the observed geographical
variation in GCA incidence. This is consistent with an
autoimmune aetiology for GCA [32]. However, we found
additional variation in susceptibility (Table 5) and inci-
dence (Fig. 1a, b) that is not fully explained by HLA-
DRB1*04 and is likely to relate to additional, unknown
genetic and environmental factors. Previous studies of
GCA have also demonstrated an association between
HLA-DRB1*04 and visual loss [33] and also with gluco-
corticoid resistance [34]. Of interest, in Japan (where
HLA-DRB1*04 population frequency is low), large-vessel
vasculitis (Takayasu arteritis) is relatively more com-
mon than GCA. Takayasu arteritis was associated with
alleles containing the 11-13-33 V-H-H motif (HLA-
DRB1*0405) in a Turkish population but was not asso-
ciated with another allele also containing V-H-H
(HLA-DRB1*0401) in a European-American popula-
tion; HLA-DRB1*1502, which was associated with
Takayasu arteritis in both populations [35], does not
contain the V-H-H motif. Very few patients in our
dataset had large-vessel imaging, but genetic character-
isation of the subset of GCA patients who have large-
vessel involvement or temporal artery sparing or both
[26] would be of interest in future studies. From a clin-
ical perspective, further study of well-phenotyped co-
horts is required to determine whether HLA-DRB1*04
may serve as a biomarker of pathophysiologically rele-
vant phenotypic disease subsets in order to develop
better risk stratification, prediction of response to glu-
cocorticoids, and ultimately targeted therapies.Additional files
Additional file 1: Appendices I and II (Membership of consortia).
Description of contents: Names and institutional affiliations of members
of the UK GCA Consortium (Appendix I) and the UKRAG Consortium
(Appendix II).
Additional file 2: Amino acids at hypervariable regions (HVR) in
susceptibility, protective, and neutral GCA alleles. Table showing the
amino acid residues in the hypervariable regions of HLA-DRB1, for each of
the HLA-DRB1 alleles. Shaded columns denote the proposed 11-13-33
GCA risk motif.Abbreviations
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